These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 20025697)

  • 41. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
    Roguin A; Bomma CS; Nasir K; Tandri H; Tichnell C; James C; Rutberg J; Crosson J; Spevak PJ; Berger RD; Halperin HR; Calkins H
    J Am Coll Cardiol; 2004 May; 43(10):1843-52. PubMed ID: 15145110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
    Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
    J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults.
    Chatrath R; Porter CB; Ackerman MJ
    Mayo Clin Proc; 2002 Mar; 77(3):226-31. PubMed ID: 11888025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term follow-up of a pediatric cohort with short QT syndrome.
    Villafañe J; Atallah J; Gollob MH; Maury P; Wolpert C; Gebauer R; Watanabe H; Horie M; Anttonen O; Kannankeril P; Faulknier B; Bleiz J; Makiyama T; Shimizu W; Hamilton RM; Young ML
    J Am Coll Cardiol; 2013 Mar; 61(11):1183-91. PubMed ID: 23375927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.
    Olde Nordkamp LR; Dabiri Abkenari L; Boersma LV; Maass AH; de Groot JR; van Oostrom AJ; Theuns DA; Jordaens LJ; Wilde AA; Knops RE
    J Am Coll Cardiol; 2012 Nov; 60(19):1933-9. PubMed ID: 23062537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.
    Conte G; Sieira J; Ciconte G; de Asmundis C; Chierchia GB; Baltogiannis G; Di Giovanni G; La Meir M; Wellens F; Czapla J; Wauters K; Levinstein M; Saitoh Y; Irfan G; Julià J; Pappaert G; Brugada P
    J Am Coll Cardiol; 2015 Mar; 65(9):879-88. PubMed ID: 25744005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain.
    van Rees JB; Borleffs CJ; Thijssen J; de Bie MK; van Erven L; Cannegieter SC; Bax JJ; Schalij MJ
    Europace; 2012 Jan; 14(1):66-73. PubMed ID: 21920909
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
    Costantini O; Hohnloser SH; Kirk MM; Lerman BB; Baker JH; Sethuraman B; Dettmer MM; Rosenbaum DS;
    J Am Coll Cardiol; 2009 Feb; 53(6):471-9. PubMed ID: 19195603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.
    Sacher F; Probst V; Maury P; Babuty D; Mansourati J; Komatsu Y; Marquie C; Rosa A; Diallo A; Cassagneau R; Loizeau C; Martins R; Field ME; Derval N; Miyazaki S; Denis A; Nogami A; Ritter P; Gourraud JB; Ploux S; Rollin A; Zemmoura A; Lamaison D; Bordachar P; Pierre B; Jaïs P; Pasquié JL; Hocini M; Legal F; Defaye P; Boveda S; Iesaka Y; Mabo P; Haïssaguerre M
    Circulation; 2013 Oct; 128(16):1739-47. PubMed ID: 23995538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
    Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
    J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
    DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry.
    Schwartz PJ; Spazzolini C; Priori SG; Crotti L; Vicentini A; Landolina M; Gasparini M; Wilde AA; Knops RE; Denjoy I; Toivonen L; Mönnig G; Al-Fayyadh M; Jordaens L; Borggrefe M; Holmgren C; Brugada P; De Roy L; Hohnloser SH; Brink PA
    Circulation; 2010 Sep; 122(13):1272-82. PubMed ID: 20837891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence and characteristics of appropriate and inappropriate therapies in recipients of ICD implanted for primary prevention of sudden cardiac death.
    Kreuz J; Balta O; Liliegren N; Mellert F; Esmailzadeh B; Nickenig G; Schwab JO
    Pacing Clin Electrophysiol; 2007 Jan; 30 Suppl 1():S125-7. PubMed ID: 17302687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Midterm Results of Implantable Cardioverter Defibrillators in Children and Young Adults from a Single Center in Turkey.
    Aykan HH; Karagoz T; Gulgun M; Ertugrul I; Aypar E; Ozer S; Alehan D; Celiker A; Ozkutlu S
    Pacing Clin Electrophysiol; 2016 Nov; 39(11):1225-1239. PubMed ID: 27620455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of beta-blockers in patients with an implantable cardioverter defibrillator.
    LaPointe NM; Stafford JA; Pappas PA; Al-Khatib SM; Anstrom KJ
    Ann Pharmacother; 2009 Jul; 43(7):1189-96. PubMed ID: 19567655
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of outcomes for patients receiving implantable cardioverter defibrillators for primary vs secondary-prevention.
    Giedrimas A; Giedrimiene D; Guertin D; White CM; Clyne CA; Kluger J
    Conn Med; 2008; 72(6):329-33. PubMed ID: 18610705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.